ArticleDermatology practical & conceptual2026
Assessing Treatment Response to PD-1 Inhibitors in Cutaneous Squamous Cell Carcinoma: Real-World Challenges.
Article in Dermatology practical & conceptual, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionCutaneous squamous cell carcinoma (cSCC) is a common nonmelanoma skin cancer primarily driven by chronic sun exposure and advanced age. Standard treatments include wide local excision, Mohs surgery, and radiotherapy, with advanced cases often managed with chemotherapeutics. PD1 inhibitors like cemiplimab and pembrolizumab are FDA-approved treatments that have shown efficacy in locally advanced or metastatic cSCC not amenable to surgery or radiation.
objectivesThis study evaluated clinical responses to these inhibitors using RECIST 1.1 criteria through direct visual examination, addressing the applicability of the criteria in real-world clinical practice.
methodsA cohort of 12 patients with cSCC treated at Duke University with cemiplimab or pembrolizumab was identified through the DeDUCE database using ICD-10 codes. Clinical responses were determined using RECIST 1.1 and modified WHO criteria and compared against clinical-based assessments.
resultsResults indicated varied responses: seven patients with progressive disease (PD), two with stable disease (SD), and three with complete response (CR). Challenges included distinguishing true progression from reactive conditions like erosive pustular dermatosis (EPD) and pseudoprogression as well as evaluating partial responses in ulcerated lesions, which are not defined within the criteria. Radiologic findings often required corroboration with clinical evaluations to avoid misclassification.
conclusionsAccurate clinical determination of cSCC response to PD-1 inhibitors is complex, requiring multidisciplinary approaches and meticulous wound care. Incorporating these clinical nuances into revised response criteria would enhance treatment decision-making, balancing the risks of premature discontinuation against prolonged ineffective therapy.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.